Your session is about to expire
← Back to Search
Lenalidomide for Multiple Myeloma
Study Summary
This trial compares lenalidomide to a placebo in treating patients with multiple myeloma who are undergoing autologous stem cell transplant.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am fully active or restricted in physically strenuous activity but can do light work.My lungs work well enough to breathe without symptoms.My multiple myeloma is active and needs treatment, and I've responded to initial therapy.I started my first cancer treatment less than a year ago.I have collected the required number of stem cells for my treatment.My cancer did not worsen after my first treatment, and I've had no more than two treatment plans.I am not pregnant or nursing and will follow strict birth control measures if of childbearing age.I have not had any blood, bone marrow, or organ transplant.I do not have any serious infections right now.My heart pumps well, with an ejection fraction of 40% or higher.I have had less than a year of treatment, including specific medications.My diabetes is under control.
- Group 1: Arm II (melphalan, autologous PBSCT, placebo)
- Group 2: Arm I (melphalan, autologous PBSCT, lenalidomide)
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are octogenarians being accepted into this research study?
"This particular clinical trial is open to patients that are aged between 18-70."
For what illnesses is Autologous Hematopoietic Stem Cell Transplantation most often the go-to treatment?
"Autologous Hematopoietic Stem Cell Transplantation is most commonly used for treatment of chronic lymphocytic leukemia. However, it can also be used as a form of treatment for stage i mycosis fungoides, at least two prior systemic chemotherapy regimens, polycythemia vera (pv)."
Are there any specific types of people who should not sign up for this trial?
"This study is meant for stage i plasma cell myeloma patients between 18 and 70 years old. They are looking for around 460 individuals in total."
Are there different hospitals in this city participating in this research project?
"Presently, this clinical trial is running in 100 locations, some notable ones being Havana, Minneapolis and Peoria. If you're considering participating in this trial, know that it might be most convenient for you to select a location that is close to where you live."
Could you please summarize the Autologous Hematopoietic Stem Cell Transplantation research that has been conducted thus far?
"City of Hope Comprehensive Cancer Center was the first to study Autologous Hematopoietic Stem Cell Transplantation in 1997. Since the initial study, there have been 1124 completed clinical trials. Currently, there are 408 clinical trials recruiting patients, many of which are based in Havana, Illinois."
Does the FDA recognize Autologous Hematopoietic Stem Cell Transplantation as a viable treatment?
"Autologous hematopoietic stem cell transplantation has some efficacy data from Phase 3 trials and thus our team rates it as a 3 in terms of safety."
Are researchers still recruiting participants for this experiment?
"The listing for this clinical trial on clinicaltrials.gov indicates that the research team is not presently recruiting patients. Although, this may be due to the fact that the trial was first posted on December 15th, 2004 and was last updated on July 27th, 2022. There are 1235 other studies that are actively recruiting patients."
Share this study with friends
Copy Link
Messenger